Schema
J.Molner
Name: J.Molner AS
Core business: Biotechnology
Date of registration: 22.09.2022
Auditor: Grant Thornton Baltic OÜ
Date of Admission to Trading: 10.11.2022 (First North Share List)
Certified adviser: Ellex Raidla Law Firm
Market: Nasdaq Tallinn
Other listings: -
Management Board:
Jason Michael Atticus Grenfell-Gardner
Supervisory Board:
Karita Sall, Yoann John Ricau, Martin Wilson
Background Information
J. Molner is a pharmaceutical company with Estonian roots aimed at providing its customers with the highest level of generic drugs for specialty generic pharmaceuticals with a focus on the USA and Canadian markets. We also provide our service clients with analytical chemistry services and cost-saving commercial stability solutions. J. Molner’s activities are based on its high-tech laboratory capable of performing a wide range of chemical analyses and studies that may be required for drug development and verifying the quality and content of various pharmaceuticals. J. Molner has the required know-how, personnel, and means to develop various generic drugs with a core focus on sterile injectable and non-sterile topical formulations.
Contact Details
Address: Akadeemia tee 21/5, 12618 Tallinn, Estonia
E-mail: jmolner@jmolner.com
Internet webpage: https://www.jmolner.com/
Contact person: Jason Michael Atticus Grenfell-Gardner (Chairman of the Management Board)